Tel: 01202 443064

11 Shelley Road, Bournemouth, Dorset, BH1 4JQ

Please note: inclusion of articles on this page does not imply endorsement or approval by Osteoporosis Dorset.
15 Nov

New NICE bisphosphonate guidance

The following information is taken from the NOS.

Leading osteoporosis experts have warned GPs and healthcare professionals to exercise caution over recently issued guidance about the use of bisphosphonates.

The new guidance, published by NICE during the summer, incorporates both fracture risk assessment tools and the availability of low-cost generic forms of bisphosphonates and concludes these drugs are cost-effective at very low fracture risk thresholds.

The appraisal recommends treatment with oral bisphosphonates for people with a probability of major osteoporotic fracture (eg, hip, spine, wrist, or humerus) that exceeds 1%  over 10 years and treatment with intravenous bisphosphonates for those with a probability of more than 10%.

At the time, NICE’s Professor Carole Longson MBE said the guidance would “provide clarity for health professionals about when to start treatment with bisphosphonates and  provide people who have osteoporosis with access to the most cost-effective treatments to prevent them getting a fracture.”

But, in a letter published in leading health journal the Lancet, clinicians including Nicholas Harvey, Juliet Compston, John Kanis and Eugene McCloskey warned that “the strict application of cost-effectiveness thresholds for inexpensive drugs might lead to counterintuitive and potentially harmful guidance.”

“Unthinking assimilation of the NICE multiple technology appraisal risks a generation of older individuals taking a bisphosphonate regardless of the individual benefit-to-risk ratio and an increased burden of rare long-term side-effects across the population. Given recent debates about the role of pharmaceutical interventions in the prevention of several chronic noncommunicable diseases, this would be an unexpected and unwelcome consequence of national guidance,” the letter concludes.

The National Osteoporosis Society’s Clinical Director Fizz Thompson said the letter highlighted an important issue.

“The National Osteoporosis Society works hard to ensure people affected by osteoporosis have access to a range of safe and effective treatments and that the benefits of those treatments outweigh the risks. It will be important that prescribing clinicians understand the concerns expressed in this letter and use existing expert guidance to help guide decision making so that these drugs are used appropriately.”


Celebrating 25 years at our annual medical conference in December 2017

Annual medical conference 2017

Once again, what a huge success the annual medical conference at Bournemouth Hospital. Over 260 doctors and allied health professionals from around the South of England joined us over the two days. It was an unrivalled event for personal and professional development, and was attended by consultants, surgeons, GP’s, physiotherapists and many other health professionals dealing with bone disease.  I would like to take this opportunity to thank the staff at the Education Centre, who helped put on this successful conference and also like to thank the Annual Medical Conference Planning Committee lead by David Rhys-Jones for all their hard work. If any health professionals would like to know further information, please contact the Charity today.

We look forward to seeing you at our next event.

Diana Moran, President of Osteoporosis Dorset.

Celebrating 25 years!

We’re delighted to announce that Osteoporosis Dorset is over 25 years old in 2017! For over a quarter of a century, we’ve been providing evidence based information to the Dorset Health community and general public.

Osteoporosis Dorset has relentlessly campaigned for the last twenty five years to improve bone health in the County.

Thanks to our amazing volunteers, partners and staff, we’ve positively impacted thousands of lives since 1992. Thank you! Please join us this year as we celebrate being 25!